- Research article
- Open Access
- Open Peer Review
Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population
- Chiu-Shong Liu†1,
- Hua-Shui Hsu†1,
- Chia-Ing Li2,
- Chia-Ing Jan3,
- Tsai-Chung Li4, 5,
- Wen-Yuan Lin1,
- Tsann Lin1,
- Ya-Chien Chen6,
- Cheng-Chun Lee†7 and
- Cheng-Chieh Lin†1, 5Email author
© Liu et al; licensee BioMed Central Ltd. 2010
- Received: 4 December 2009
- Accepted: 27 May 2010
- Published: 27 May 2010
Metabolic syndrome (MetS) is composed of cardiovascular risk factors including insulin resistance, obesity, dyslipidemia, and hypertension. Most of the components of MetS have been linked to the development of neoplasm. The purpose of this study was to evaluate the relationship between individual components of MetS and colorectal adenoma.
The study subjects were recruited from a pool of 4872 individuals who underwent a health check-up examination during the period January 2006 to May 2008. Each participant fulfilled a structured questionnaire. MetS was defined based on the America Heart Association and National Heart Lung Blood Institute criteria. Subjects with history of colon cancer, colon polyps, colitis, or prior colonic surgery were excluded.
A total of 4122 subjects were included for final analysis (2367 men and 1755 women; mean age, 49.6 ± 11.7 years). Of them, MetS was diagnosed in 708 men (29.9%) and in 367 women (20.9%). Among the patients with MetS, 34.6% had adenoma, 31.7% had hyperplastic polyps and 23.3% were polyp-free (p < 0.0001, Chi-square test). The adjusted OR for colorectal adenoma was significantly higher in the subjects with MetS (OR, 1.31, CI: 1.09-1.57). A stronger association between MetS and colorectal adenoma was found in men (OR:1.44, CI:1.16-1.80) than in women (OR:1.04, CI:0.74-1.46). The adjusted OR for adenoma increased as the number of MetS components increased (p for trend = 0.0001 ). When the individual components of MetS were analyzed separately, only central obesity (OR:1.36, CI:1.14-1.63), low HDL cholesterol levels (OR:1.30, CI:1.10-1.54) and high triglyceride levels (OR:1.26, CI:1.04-1.53) were independently associated with colorectal adenoma.
Of the components of MetS analyzed in this study, central obesity and dyslipidemia are independent risk factors for colorectal adenoma. With regard to the prevention of colorectal neoplasm, life-style modification such as weight reduction is worthwhile.
- Metabolic Syndrome
- Colorectal Adenoma
- Colon Polyp
- Hyperplastic Polyp
Metabolic syndrome (MetS), a collection of cardiovascular risk factors including central obesity, high blood pressure, hyperglycemia, impaired glucose tolerance, hypertriglyceridemia, as well as low levels of high density lipoprotein cholesterol, is associated with an increased risk of cardiovascular disease and diabetes [1–3]. Interestingly, most of the components of metabolic syndrome have also been linked individually to the development of cancer [4–6].
Colorectal cancer is the second leading cause of the cancer incidence and the third leading causes of the cancer death in Taiwan . Several studies have found that obesity, dyslipidemia and hyperglycemia are risk factors for colorectal cancer [8–11]. Furthermore, recent epidemiological studies have reported a positive correlation between metabolic syndrome and the presence of colorectal adenoma [12–14]. In order to prevent colorectal cancer, it is crucial to identify the risk factors that are associated with the development of colorectal neoplasia. The aim of this study was to elucidate the relationship between the components of MetS and prevalence of colorectal adenoma in a Chinese population.
All the individuals attending China Medical University Hospital for their routine health survey, during the period January 2006 to May 2008, were invited to participate in this study. A total of 5162 subjects were invited. Colonoscopy was one of the health survey package. Each participant was asked to complete a structured questionnaire designed to collect basic demographic data, medical history and lifestyle characteristics. Smoking status and alcohol consumption history were divided into 3 classes as follows: never, former, and current. For women, history about menopause (yes/no), age of menopause, bilateral oophorectomy (yes/no), and hormone replacement history (yes/no), duration of hormone replacement, were also obtained.
All who willing to complete the health survey, age greater than 30 y/o, were included in the study. Participants with a history of colon cancer, colon polyps, colitis, or prior colonic surgery were excluded from the study. Subjects with family history of familial adenomatous polyposis and patients on life-long anticoagulant therapy with risk of biopsy, were also excluded from the study. Of the 4872 patients that were included, 513 did not sign the consent form, 117 did not complete all phases of the examination or did not undergo a polyp biopsy, and 124 were excluded because of a history of colon disease. Therefore, the final study population was 4122 individuals (2367 men and 1755 women; mean age, 49.6 ± 11.7 years).
Anthrometric index and laboratory tests
Trained staff measured height, waist and hip circumference (measured to the nearest 0.1 cm) and weight (measured to the nearest 0.1 kg). Weight was measured with light clothing. Waist circumference (WC) was taken at the midway point between the inferior margin of the last rib and the superior iliac crest in a horizontal plane. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). The same staff measured blood pressure in the right arm using an appropriately sized cuff and a standard mercury sphygmomanometer in a sitting position. Blood was drawn with minimal trauma from an antecubital vein in the morning after a 12-hour overnight fast and was sent for analysis within four hours of blood collection. Hs-CRP levels were measured by measured by nephelometry, a latex particle-enhanced immunoassay (TBA-200FR, Tokyo, Japan). The interassay and intraassay CVs were < 2.0% and < 1.9%, respectively. Biochemical markers such as total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride, fasting glucose, creatinine, and uric acid were analyzed by a biochemical autoanalyzer (Beckman Coulter, Lx-20, USA) at the Department of Clinical Laboratory Diagnostics, China Medical University Hospital.
MetS was defined clinically, based on the presence of three or more of the following America Heart Association and National Heart Lung Blood Institute (AHA/NHLBI) metabolic syndrome criteria : (1) central obesity (waist circumference >0.9 m in men, and ≥0.8 m in women), (2) high triglyceride level (≥ 1.7 mmol/L or on drug treatment for elevated triglycerides), (3) low HDL-C level (< 0.9 mmol/L in men and < 1.1 mmol/L in women or on drug treatment for reduced HDL-C), (4) high blood pressure (systolic BP≥ 130 mmHg or diastolic BP≥ 85 mmHg or under anti-hypertensive drug treatment in patients with a history of hypertension), (5) high fasting plasma glucose concentration (≥ 5.6mmol/L or on drug treatment for elevated glucose).
Bowel preparation was done with polyethylene glycol lavage (Klean Prep Powder®, Helsinn-Birex Pharmaceuticals, Dublin, Ireland) using a standard protocol identical to that used for diagnostic colonoscopy. The screening colonoscopy was performed by a gastroenterologist. The colonoscope was inserted up to ileocecal area under intravenous general anesthesia with dormicum and alfentanil. Colonoscopic findings were categorized as polyp-free; hyperplastic polyp (no potential of cancer change); low grade adenoma; and high grade adenoma. A neoplasm was classified as a high-grade adenoma based on the following features: a diameter of >1 cm, the presence of three or more lesions, a villous component, or high-grade dysplasia . All the specimen were classified following a pathological examination at the Department of Pathology, China Medical University Hospital. It has been qualified by American College of Pathologist.
The data are presented as mean ± standard deviation (SD) unless indicated otherwise. Log transformation was used for variables with significant deviation from normal distribution, followed by assessment by the Kolmogorov-Smirnov test before further analyses. Analysis of variance (ANOVA) was used for comparison of continuous variables. ANOVA with Scheffe's post hoc comparisons was used. Each pair of the two groups' post hoc comparison was statistically significant at α = 0.0036. Chi-square analysis was used to compare the differences in prevalence of colon neoplasia across MetS groups. Multinominal logistic regression analysis was used to estimate the ORs of colon polyps by age, MetS status, smoking and alcohol consumption status. These statistical analyses were performed using the PC version of SAS statistical software (SAS 9.1.3 Service Pack 2, SAS Institute Inc., Cary, NC, USA). A two-sided p-value of less than 0.05 was considered significant.
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. Ethics approval for patient recruitment and analyzing the data was obtained from the Institutional Review Board of China Medical University Hospital in Taiwan.
Prevalence (%) of metabolic syndrome (MetS), its individual components and colon polyps by sex
Women (n = 1755)
Men (n = 2367)
Total (N = 4122)
MetS (AHA/NHLBI criteria)
Elevated fasting glucose
Number of components present
Low grade adenoma
High grade adenoma
Demographic and clinical characteristics of the subjects according to colonoscopic findings
Normal (0) N = 3062
Hyperplastic polyp (1) N = 341
Low-grade neoplasm (2) N = 579
High-grade neoplasm (3) N = 140
ANOVA Scheffe's test b
48.2 ± 11.5
51.5 ± 10.8
53. 5 ± 11.1
58.2 ± 11.4
23.7 ± 3.6
24.7 ± 3.3
24.6 ± 3.4
24.1 ± 3.5
0.80 ± 0.10
0.84 ± 0.91
0.84 ± 0.96
0.84 ± 0.99
117.6 ± 15.0
120.5 ± 14.7
121.8 ± 15.4
121.8 ± 15.6
74.3 ± 9.4
76.7 ± 9.9
76.7 ± 9.3
77.2 ± 8.8
5.33 ± 1.40
5.59 ± 1.69
5.45 ± 1.14
5.50 ± 1.28
5.14 ± 0.99
5.14 ± 1.09
5.22 ± 1.04
5.23 ± 0.95
1.30 ± 1.00
1.44 ± 0.95
1.49 ± 1.06
1.43 ± 1.25
1.16 ± 0.34
1.07 ± 0.32
1.07 ± 0.32
1.09 ± 0.33
0.08 ± 3.45
0.09 ± 3.52
0.12 ± 3.39
0.12 ± 3.09
Smoking status *a
Alcohol drinking *a
Crude and adjusted odds ratios for colon polyps associated with metabolic syndrome and its components (N = 4122)
Hyperplastic polyp N = 341
Adenoma (low and high grade) N = 719
N = 2944
Number of metabolic syndrome components
1 (N = 1168)
2 (N = 914)
3 (N = 702)
> = 4 (N = 476)
Metabolic syndrome components
Large waist (N = 1179)
High BP (N = 1376)
Low HDL-C (N = 2389)
High triglyceride (N = 1030)
High glucose (N = 1149)
Adjusted* ORs for colon polyps associated with metabolic syndrome (MetS) and its component according to gender
N = 104
Adenoma (low or high grade) N = 232
N = 237
Adenoma (low or high grade) N = 487
Component of MetS
The prevalence of MetS is increasing due to the escalation of obesity and sedentary lifestyle worldwide. The present study confirmed that certain components of MetS increase the likelihood of colorectal adenoma, a premalignant lesion of colorectal cancer.
Previous studies have found that MetS increases the risk of colorectal adenoma by 1.3 to 2 times [12–14, 17]. In present study, we addressed the relationship between colorectal adenoma and the various features of MetS. Kim  found that only large waist circumference was associated with the development of colon adenoma. Lee  and Wang  found that BMI and high triglyceride levels were related to the development of colon or rectosigmoid adenoma. We found that large waist circumference and atherogenic dyslipidemia (low HDL-C and high triglyceride) were associated with the development of colorectal adenoma when individual components were analyzed separately. It is the first time to find the relationship of colorectal adenoma and low serum HDL-C level in the literature.
The possible mechanisms by which colorectal neoplasms arise in subjects with MetS comprise inflammation, insulin resistance and oxidative stress . Adipose tissue is now recognized as an endocrine organ rather than a simple fat storage site, and a wide range of inflammatory cytokines is released from adipose tissue, including C-reactive protein, tumor necrosis factor- and interleukin-6 [19, 20]. Adipose tissue can produce and release the inflammatory cytokines that are potentially procarcinogenic. The association of colorectal adenoma and the inflammatory cytokines has been postulated [21–23]. In our study, high-sensitivity C-reactive protein level was significantly higher in MetS subjects with adenoma than in MetS subjects without polyps. This could partly explain the possible mechanism of such phenomenon. Two studies have indicated that patients with multiple components of MetS are at increased risk for colorectal cancer mortality compared with the individual components alone. Cluster analysis indicates that the effects of the individual components are additive [11, 18]. We also found that the risk for colorectal ademoma increased with the number of components of MetS.
The association between the MetS and colorectal adenoma was stronger for men than for women. Previous studies have reported the same phenomenon [13, 17]; however, those did not take menopausal status of women or the use of hormone replacement therapy into account. It is possible that the protective effect of estrogen or progesterone may be masking the true effects of metabolic syndrome on colorectal neoplasms. The Women's Health Initiative Estrogen Plus Progestin trial suggested that hormone replacement therapy reduced invasive colorectal cancer by 44% . However, a follow-up study of women using estrogen alone did not reveal a reduction in colorectal cancer incidence . Gunter et al postulated two pathways that are related to colon cancer; one involving endogenous estradiol, and the other involving obesity and hyperinsulinemia . In this study, we were unable to confirm whether estrogen or progesterone has a protective effect on the development of colorectal adenoma. More research is needed to clarify the reason for the gender difference in the prevalence of colorectal adenoma in patients with metabolic syndrome.
In addition to smoking and alcohol consumption, confounding factors for colon neoplasm include physical activity, and dietary variables, which were not analyzed in our study. Larsen IK et al  reveal that smoking and BMI were the most significant risk factors for neoplasia, but adhering to recommendations on diet and physical activity seems also to be important.
In our study, similar distribution of demographic characteristic between participants and non-participants were found, indicating the kind of selection error might be random. In addition, as long as individuals with the MetS and colon polyps have equal probability of having physical check-up as those individuals with MetS but no colon polyps, the detection error will be random. Thus, the biased results in the effect may be toward the null, a lesser threat to validity.
To evaluate the potential misclassification of polyps/adenoma, we measured the concordance rate of the pathologists. The Kendall's Tau-b statistic was 0.978, which meant a very high inter-rater reliability. The possibility of outcome misclassification was minimal. There also exists the possibility of a measurement error. The inter-assay and intra-assay CVs for cholesterol, triglyceride, glucose and HDL-C were < 4% and < 3%, respectively. Such a measurement error is independent of colon polyp, i.e., due to random error, the results in the effect may be toward the null, a lesser threat to validity.
The present study of Chinese men and women revealed that increased likelihood of colorectal adenoma, a premalignant lesion of colorectal cancer, was associated with MetS. Of them, central obesity and dyslipidemia were independently increased for the risk of colorectal adenoma. With regard to the prevention of colorectal cancer, life-style modification such as weight reduction is worthwhile.
This study was supported by grant from the China Medical University Hospital (DMR-96-084), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH99-TD-B-111-004) and National Science Council (NSC96-2628-B-039-011-MY3).
The authors express their special thanks to the staff and subjects who participated in this study.
We certify that all our affiliations with or financial involvement in, within the past 5 years and foreseeable future, any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed.
- Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999, 83 (9B): 25F-29F. 10.1016/S0002-9149(99)00211-8.View ArticlePubMedGoogle Scholar
- Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52 (5): 1210-1214. 10.2337/diabetes.52.5.1210.View ArticlePubMedGoogle Scholar
- Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005, 56: 45-62. 10.1146/annurev.med.56.082103.104751.View ArticlePubMedGoogle Scholar
- Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348 (17): 1625-1638. 10.1056/NEJMoa021423.View ArticlePubMedGoogle Scholar
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM: Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005, 293 (2): 194-202. 10.1001/jama.293.2.194.View ArticlePubMedGoogle Scholar
- Lukanova A, Bjor O, Kaaks R, Lenner P, Lindahl B, Hallmans G, Stattin P: Body mass index and cancer: results from the Northern Sweden Health and Disease Cohort. Int J Cancer. 2006, 118 (2): 458-466. 10.1002/ijc.21354.View ArticlePubMedGoogle Scholar
- Bureau of Health Promotion, Department of Health, Taiwan: Taiwan Cancer Registry 2008. 2010, Accessed: March 22, [http://www.bhp.doh.gov.tw/BHPnet/English/index.aspx]Google Scholar
- Giovannucci E: Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002, 31: 925-43. 10.1016/S0889-8553(02)00057-2.View ArticlePubMedGoogle Scholar
- Limburg PJ, Anderson KE, Johnson TW, Jacobs DR, Lazovich D, Hong CP, Nicodemus KK, Folsom AR: Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005, 14 (1): 133-137.PubMedGoogle Scholar
- Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR: The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006, 107 (1): 28-36. 10.1002/cncr.21950.View ArticlePubMedGoogle Scholar
- Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K: Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002, 11 (4): 385-391.PubMedGoogle Scholar
- Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH: Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol. 2005, 20 (9): 1410-1415. 10.1111/j.1440-1746.2005.03971.x.View ArticlePubMedGoogle Scholar
- Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S: The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev. 2005, 6 (4): 485-489.PubMedGoogle Scholar
- Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rhee PL, et al: Is metabolic syndrome a risk factor for colorectal adenoma?. Cancer Epidemiol Biomarkers Prev. 2007, 16 (8): 1543-1546. 10.1158/1055-9965.EPI-07-0199.View ArticlePubMedGoogle Scholar
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112 (17): 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.View ArticlePubMedGoogle Scholar
- Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992, 326 (10): 658-662. 10.1056/NEJM199203053261002.View ArticlePubMedGoogle Scholar
- Lee GE, Park HS, Yun KE, Jun SH, Kim HK, Cho SI, Kim JH: Association between BMI and metabolic syndrome and adenomatous colonic polyps in Korean men. Obesity (Silver Spring). 2008, 16 (6): 1434-1439. 10.1038/oby.2008.216.View ArticleGoogle Scholar
- Cowey S, Hardy RW: The metabolic syndrome: A high-risk state for cancer?. Am J Pathol. 2006, 169 (5): 1505-1522. 10.2353/ajpath.2006.051090.View ArticlePubMedPubMed CentralGoogle Scholar
- Trayhurn P, Beattie JH: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001, 60 (3): 329-339. 10.1079/PNS200194.View ArticlePubMedGoogle Scholar
- Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004, 92 (3): 347-355. 10.1079/BJN20041213.View ArticlePubMedGoogle Scholar
- Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006, 15 (6): 1126-1131. 10.1158/1055-9965.EPI-06-0042.View ArticlePubMedGoogle Scholar
- Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS: Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008, 68 (1): 323-328. 10.1158/0008-5472.CAN-07-2924.View ArticlePubMedPubMed CentralGoogle Scholar
- Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F: Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001, 10 (9): 937-941.PubMedGoogle Scholar
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288 (3): 321-333. 10.1001/jama.288.3.321.View ArticlePubMedGoogle Scholar
- Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, et al: Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008, 17 (10): 2609-2618. 10.1158/1055-9965.EPI-08-0385.View ArticlePubMedPubMed CentralGoogle Scholar
- Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, et al: Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008, 68 (1): 329-337. 10.1158/0008-5472.CAN-07-2946.View ArticlePubMedPubMed CentralGoogle Scholar
- Larsen IK, Grotmol T, Almendingen K, Hoff G: Lifestyle as a predictor for colonic neoplasia in asymptomatic individuals. BMC Gastroenterol. 2006, 6: 5-10.1186/1471-230X-6-5.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/10/51/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.